Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line

Publisher： Karger

E-ISSN： 1423-0232|89|6|319-331

ISSN： 0030-2414

Source： Oncology, Vol.89, Iss.6, 2015-10, pp. : 319-331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

By  

Oncology, Vol. 70, Iss. 5, 2007-01 ,pp. : 330-338

Karger

Access to resources Recommend Favorite

A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-02 ,pp. : 101-105

Karger

Access to resources Recommend Favorite

Xeloda® in the Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 57, Iss. 1, 1999-07 ,pp. : 16-20

Karger

Access to resources Recommend Favorite

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 37-42

Karger

Access to resources Recommend Favorite

Paclitaxel, Epirubicin and Cyclophosphamide Combination in First-Line Treatment of Metastatic Breast Cancer: A Dose Escalation Study

By  

Oncology, Vol. 66, Iss. 3, 2004-06 ,pp. : 185-191

Karger

Access to resources Recommend Favorite